MYOSCINT
LOE Approachingimciromab pentetate
BLAVIAL
Approved
Jul 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18m ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYOSCINT (imciromab pentetate) is a radiopharmaceutical diagnostic agent approved in 1996 for cardiac imaging. The drug is administered as a vial injection and is used to detect myocardial infarction and assess cardiac viability. It functions as a targeted imaging agent that localizes to damaged or ischemic myocardial tissue.
LOE Approaching
Product is approaching loss of exclusivity with minimal linked job opportunities, suggesting a small or declining brand team focused on lifecycle management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MYOSCINT has zero linked job openings, indicating minimal active hiring and a very small or outsourced commercial footprint. Working on this product would involve managing a legacy diagnostic asset with declining market relevance in an increasingly digital imaging landscape.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.